| Literature DB >> 25127144 |
Lia Panman1, Maria Papathanou2, Ariadna Laguna3, Tony Oosterveen4, Nikolaos Volakakis2, Dario Acampora5, Idha Kurtsdotter3, Takashi Yoshitake6, Jan Kehr6, Eliza Joodmardi2, Jonas Muhr3, Antonio Simeone5, Johan Ericson7, Thomas Perlmann8.
Abstract
Distinct midbrain dopamine (mDA) neuron subtypes are found in the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA), but it is mainly SNc neurons that degenerate in Parkinson's disease. Interest in how mDA neurons develop has been stimulated by the potential use of stem cells in therapy or disease modeling. However, very little is known about how specific dopaminergic subtypes are generated. Here, we show that the expression profiles of the transcription factors Sox6, Otx2, and Nolz1 define subpopulations of mDA neurons already at the neural progenitor cell stage. After cell-cycle exit, Sox6 selectively localizes to SNc neurons, while Otx2 and Nolz1 are expressed in a subset of VTA neurons. Importantly, Sox6 ablation leads to decreased expression of SNc markers and a corresponding increase in VTA markers, while Otx2 ablation has the opposite effect. Moreover, deletion of Sox6 affects striatal innervation and dopamine levels. We also find reduced Sox6 levels in Parkinson's disease patients. These findings identify Sox6 as a determinant of SNc neuron development and should facilitate the engineering of relevant mDA neurons for cell therapy and disease modeling.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25127144 DOI: 10.1016/j.celrep.2014.07.016
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423